This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Subscribe To Our Newsletter & Stay Updated
